NYSE:ZTSPharmaceuticals
A Look At Zoetis (ZTS) Valuation As Softer Sales Projections Stir Debate Before Q4 2025 Earnings
Zoetis (ZTS) heads into its upcoming Q4 2025 earnings release with investor attention fixed on softer sales projections for certain pet and livestock medicines and debate around a key arthritis drug’s recent performance.
See our latest analysis for Zoetis.
Zoetis shares currently trade at US$124.65. The recent 90 day share price return of a 13.47% decline and 1 year total shareholder return of a 23.86% decline suggest momentum has been fading as investors reassess growth expectations and risk...